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Summary
Background: The present study was conducted to clarify whether azelnidipine might
have beneﬁcial effects on autonomic functions, and whether such beneﬁcial effects
might affect the vascular functions (i.e., arterial stiffness and endothelial function).
Methods and results: This study with a cross-over design was conducted in 21
hypertensive patients (65± 9 years old) being treated with calcium channel block-
ers (CCBs) other than azelnidipine or benidipine (i.e., during the study period,
the CCB was switched to either azelnidipine 16mg/day or benidipine 4mg/day,
administered alternately for 8 weeks each). Blood examinations were conducted
and the heart rate variability, baro-receptor sensitivity (BRS), brachial-ankle pulse
wave velocity (baPWV) and ﬂow-mediated vasodilatation (FMD) in the brachial
artery were measured after treatment with each of the two drugs. While the
blood pressure levels decreased to a similar degree after both treatments, the
BRS (8.8± 5.5ms/mmHg vs. 6.4± 2.9ms/mmHg, p < 0.01) and high-frequency power
component (HF: 139±152ms2/Hz vs. 88± 97ms2/Hz) were higher after treatment
with azelnidipine than after treatment with benidipine (p < 0.05). However, the
baPWV, FMD and plasma levels of malonyldialdehyde low-density lipoprotein choles-
terol and nitric oxides were similar after treatment with both drugs.
Conclusion: Azelnidipine has greater beneﬁcial effects on the autonomic functions
than benidipine although the degree of reduction of blood pressure induced by the
two drugs was similar. However, this greater beneﬁcial effect of azelnidipine on the
autonomic functions did no
azelnidipine and benidipine
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ntroduction
alcium channel blockers (CCBs) activate the
ympathetic nervous system via their potent vasodi-
atatory effect, and this activation is thought to be
armful to the cardiovascular system [1,2]. There-
ore, several guidelines on the management of
ypertension recommend the use of long-acting,
ut not short-acting CCBs for the management of
ypertension [3—5]. Apart from these pharmaco-
ogic characteristics, some CCBs have also been
emonstrated to exert direct inhibition on the
ympathetic nervous activity [6—8]. While some
xperimental studies have reported the inhibitory
ffect of azelnidipine on the sympathetic nervous
ctivity [6,9], the beneﬁcial effects of this drug on
he autonomic functions has not yet been clearly
emonstrated in the clinical setting. Recently, it
as been demonstrated that markers of vascular
unction, such as arterial stiffness and endothelial
unction parameters can predict the risk of future
ardiovascular events [10—13]. In this connection,
ympathetic nervous system activation may impair
he vascular functions via several mechanisms,
ncluding by increasing the arterial tone, increas-
ng oxidative stress, and/or activating inﬂammation
14—17]. If azelnidipine exerted beneﬁcial effects
n the autonomic functions, it may also indirectly
mprove the vascular functions.
The present study was conducted to clarify
hether azelnidipine might have a beneﬁcial effect
n the autonomic functions and whether such a
eneﬁcial effect might also affect the vascular
unctions.
ethods
ubjects
atients treated for essential hypertension at Tokyo
edical University Hospital who met the follow-
ng study protocol criteria were consecutively
nrolled in the present study. The patient cri-
eria for inclusion in this cross-over study were:
1) being treated with amlodipine 5mg/day or
ifedipine retard 40mg/day for >6 months prior
o enrollment in this study; (2) blood pres-
ure controlled at <140/90mmHg for at least 6
onths before the start of this study while on
he aforementioned medication; (3) no history
f atherosclerotic cardiovascular diseases or seri-
us illnesses requiring speciﬁc medical treatment,
xcept statin treatment for hypercholesterolemia;
4) postmenopausal women were only enrolled if
ot on hormone replacement therapy; (5) avail-
c
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bility of informed consent prior to the subject’s
articipation in the study. The protocol of the study
as approved by the Ethics Committee of Tokyo
edical University.
edication protocol
his study was performed using a cross-over design
ith a single-blind protocol to avoid biases (i.e.,
o information about the prescribed medication
as provided to the examiners who assessed the
orearm post-ischemic hyperemia or conducted the
ata analyses). During the run-in period for this
tudy, the patients were treated with their routine
edication (i.e., amlodipine 5mg/day or nifedip-
ne retard 40mg/day) for an additional 8 weeks.
hereafter, the patients were randomly allocated
o azelnidipine treatment at the dose of 16mg/day
r benidipine, which reported its possible adverse
ffect on sympathetic nervous system [18], treat-
ent at the dose of 4mg/day. Both drugs were
lternately administered to the patients in a cross-
ver manner for 8 weeks each (without a washout
eriod). These doses of the respective CCBs are
hose usually used in clinical practice for the treat-
ent of hypertension in Japanese patients. In
atients who were receiving other antihyperten-
ive drugs in addition to the CCB and/or a statin
efore entering the study, these drugs were con-
inued during the medication protocol period. If at
ny time-point during the study period, the blood
ressure exceeded 160/100mmHg, the subject
as withdrawn from the protocol. Assessment of
he autonomic functions [baro-receptor sensitivity
BRS) and heart rate variability], the measurement
f the brachial-ankle pulse wave velocity (baPWV)
nd ﬂow-mediated vasodilatation of the brachial
rtery (FMD), and blood sampling were performed
n the ﬁnal day of the treatment period with each
f the drugs (the examination day). The medication
rotocol was managed by one of the investigators
H.T.), with the examiners conducting the above
ests being blinded to any information regarding the
edication.
All of the study subjects underwent routine blood
xamination (measurement of the plasma levels of
ow-density lipoprotein cholesterol, triglycerides,
igh-density lipoprotein cholesterol and glucose),
chocardiography (measurement of the left ven-
ricular mass index and left ventricular ejectionarotid artery (measurement of the intima-media
hickness of the common carotid artery and the
laque score) [20] within 6 months prior to their
ntry into this protocol.
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Assessment of the autonomic functions and
measurement of the brachial-ankle pulse
wave velocity and ﬂow-mediated
vasodilatation
On the morning (7:00—7:30 a.m.) of the measure-
ment day, the prescribed drug (i.e., azelnidipine
or benidipine) was taken by the subjects with
small amount of water. The patients were allowed
to rest in the sitting position in a quiet, dark,
air-conditioned room (22—25 ◦C) for 5min in the
morning (9:00—10:30 a.m.). Then, the blood
pressure and heart rate were determined by oscillo-
metric methods (OMRON Colin, Kyoto, Japan). After
this measurement, the patients were allowed to
rest in the supine position in the same room. Then,
after the subjects had rested for at least 15min,
the following measurements were conducted; the
subjects had been instructed to fast for at least 8 h
and to abstain from alcohol, smoking, caffeine and
antioxidant vitamins for at least 12 h prior to the
measurements.
After 15min rest in the supine position, the sys-
tolic blood pressure and heart rate were recorded
for 10min in the supine position using arterial
tonometry and electrocardiography (Jentow-7700,
OMRON COLIN, Kyoto, Japan). These measurements
were not controlled for the phase of respiration.
The spontaneous BRS and heart rate variability
were determined from these samples using a com-
mercial software (GMview II, Signalysis, Tokyo,
Japan) [21]. In the assessment of the BRS, all of
the subjects demonstrated a correlation coefﬁcient
of >0.85 between the systolic blood pressure and
the R—R interval. From the samples of R—R inter-
vals, the high-frequency power (HF) component,
low-frequency power (LF) component and the ratio
of the LF and HF (LF/HF) were calculated.
After the assessment of the autonomic functions,
the baPWV was measured (FORM, OMRON Colin,
Kyoto, Japan). The details of the measurement are
described elsewhere [22]. Then, measurement of
the FMD was conducted. Ultrasound measurements
were performed according to the guidelines for
ultrasound assessment of the FMD of the brachial
artery [23]. Using high-resolution ultrasound (Unex
Co. Ltd., Nagoya, Japan) with a 10MHz linear array
transducer, measurements of the right brachial
artery diameter were taken at rest, after cuff deﬂa-
tion following suprasystolic compression (30mmHg
above systolic pressure) of the right upper arm
for 5min. The longitudinal image of the artery
was recorded at the baseline, continuously from
30 s before to 2min after the cuff deﬂation, and
for 5min after sublingual nitroglycerin (0.075mg)
administration. The diameter of the brachial artery
t
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as determined automatically using the instrument
Unex Co. Ltd., Nagoya, Japan). The changes in
he diameter were continuously recorded. Then,
asodilatation was estimated as the percent change
n the diameter over the baseline value at maximal
ilatation after reactive hyperemia (FMD) and after
ublingual application of glyceryl trinitrate (NGD).
aboratory measurements
lood samples were collected from fasting subjects
t an interval of at least 1 h after the assess-
ent of arterial endothelial function. The serum
evel of malonyldialdehyde low-density lipoprotein
MDA-LDL) cholesterol was determined with a com-
ercially available ELISA kit (SRL, Tokyo, Japan).
itrogen oxide (NOx) levels in the serum were
easured using a chemiluminescence technique
sing high-performance liquid chromatography sys-
em (L-7100, Hitachi Co. Ltd., Tokyo, Japan and
PD-10A, Shimazu Co. Ltd., Kyoto, Japan) [24].
tatistical analysis
ll data were expressed as means± S.D. The means
nd error bars are shown in the ﬁgures. Differences
n parameters between the two treatment periods
ere evaluated using Wilcoxon’s t-test for paired
ariables. For the parameters showing signiﬁcant
ifferences between the two treatment periods,
he time effects associated with the cross-over
esign was evaluated by logistic regression analysis
i.e. the time effect was set as an independent vari-
ble (azelnidipine was the ﬁrst prescribed drug = 1
nd benidipine was the ﬁrst prescribed drug = 0)]. A
-value of less than 0.05 was considered to indicate
statistically signiﬁcant difference. The statistical
nalyses were performed using the SPSS software
ackage (SPSS Inc., Chicago, IL).
esults
e enrolled a total of 25 consecutive patients
n this study, and 21 agreed to participate. Of
hese, 14 were receiving 5mg of amlodipine, 7 were
eceiving 40mg of nifedipine and 2 were receiving
tatin at the start of this study.
Table 1 shows the clinical characteristics of the
ubjects before the start of the run-in period.
igs. 1 and 2 show the blood pressure determined by
he oscillometric method, heart rate, HF, LF, LF/HF,
RS and R—R interval after treatment with the two
rugs. While the degree of reduction of blood pres-
ure induced by the two drugs was similar, the heart
Azelnidipine and autonomic function 117
Table 1 Clinical characteristics of the study subjects
Age 65± 9
Gender (male/female) 16/5
Smoking (%) 29%
BMI 24.0± 2.5
SBP (mmHg) 131± 13
DBP (mmHg) 79± 10
LDL (mmol/L) 2.9± 0.8
HDL (mmol/L) 1.3± 0.4
TG (mmol/L) 1.5± 0.4
FPG (mmol/L) 6.2± 0.8
LVMI (g/m2) 118± 17
LVEF (%) 69± 3
IMT (mm) 0.9± 0.2
Plaque score 4.4± 3.2
BMI, body mass index; SBP, systolic blood pressure; DBP,
diastolic blood pressure; LDL, serum low-density lipoprotein
cholesterol; HDL, serum high-density lipoprotein choles-
terol; TG, serum triglycerides; FPG, fasting plasma glucose;
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Table 2 Changes in variables during the treatment
phases with azelnidipine and benidipine
Azelnidipine Benidipine p-Value
MDA-LDL
(U/L)
126.2 ± 10.1 123.2 ± 10.6 ns
NOx
(mol/mL)
45.8 ± 8.2 36.4 ± 5.4 ns
baPWV
(cm/s)
1705 ± 67 1690 ± 71 ns
FMD (%) 4.2 ± 0.7 4.7 ± 0.6 ns
MDA-LDL, plasma level of malonyldialdehyde low-density
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tLVMI, left ventricular mass index; LVEF, left ventricular
ejection fraction; IMT, intima-media thickness of the
common carotid artery.
ate, R—R interval, BRS and the HF component were
igher after treatment with azelnidipine than after
reatment with benidipine. In this, the signiﬁcant
ime effects associated with the cross-over design
as not observed. Table 2 shows the results for the
ther parameters examined at the time of comple-
ion of the azelnidipine and benidipine treatment
eriods. The plasma levels of MDA-LDL cholesterol
nd NOx, baPWV and FMDmeasured after treatment
ith the two drugs were similar.
iscussionome experimental studies have revealed that
zelnidipine improves the BRS and attenuates
enal sympathetic activation [6,9]. In a clinical
tudy conducted by Kuramoto et al., azelnidip-
t
a
a
s
igure 1 Blood pressure and heart rate determined by the o
R is the heart rate; SBP is the systolic blood pressure; DBP
reatment.lipoprotein cholesterol; NOx, plasma levels of nitric
oxides; baPWV, brachial-ankle pulse wave velocity; FMD,
ﬂow-mediated vasodilatation in the brachial artery.
ne treatment was associated with a reduction
f the heart rate [25], and in their head-
p tilt study, Morimoto et al. demonstrated
hat azelnidipine improves the BRS [26]. While
hese studies did not directly conﬁrm the ben-
ﬁcial effects of azelnidpine on the autonomic
unctions, recently, Eguchi et al. demonstrated that
zelnidipine, but not amlodipine, improved the BRS
n patients with hypertension [27]. In addition to
easurement of the BRS, assessment of the heart
ate variability is an established method to examine
he autonomic functions [28]; in this assessment,
he HF component reﬂects the parasympathetic
one and the LF/HF component reﬂects the sympa-
hetic tone [29]. In the present study, azelnidipine
ncreased the HF and decreased the heart rate
n addition to elevating the BRS. Thus, azelnidip-
ne improves the BRS, and this might result in
reduction of the heart rate mediated by the
arasympathetic-dominant state.
Azelnidipine is a lipophilic drug and is thoughto exert effects on the central nervous system
fter crossing the blood—brain barrier [6,9]. In
ddition, some experimental studies have demon-
trated that azelnidpine might have antioxidant
scillometric method after treatment with the two drugs.
is the diastolic blood pressure. *p < 0.05 vs. benidipine
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Figure 2 HF, LF, LF/HF, BRS and R—R interval after treatment with the two drugs. BRS is the baro-receptor sensitivity;
pow
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aHF is the high-frequency power; LF is the low-frequency
frequency power. *p < 0.05 vs. benidipine treatment; †p <
effects [30]. While reduction of oxidative stress is
known to reduce the central and peripheral sympa-
thetic activity [31], azelnidipine did not affect the
plasma levels of MDA-LDL cholesterol, a marker of
oxidative stress, in this study [32]. One of the possi-
ble mechanisms of this absence of reduction in the
serum levels of the marker of oxidative stress by
azelnidipine treatment could be that the dosage of
azelnidipine used in this study was not sufﬁcient to
produce antioxidant effects. Notwithstanding, the
antioxidant effects of azelnidipine might not have
any major role in the beneﬁcial effects of the drug
on the autonomic functions.
Arterial stiffness as assessed by pulse wave
velocity, and endothelial function as assessed
by ﬂow-mediated vasodilatation are markers of
the risk of future cardiovascular events [10—13].
Sympathetic nervous activation increases the arte-
rial stiffness and impairs endothelial function via
several mechanisms, including by increasing the
arterial tone, increasing oxidative stress, and/or
activating inﬂammation [14—17]. Therefore, while
it is possible that the beneﬁcial effects of azelnidip-
ine on the autonomic functions may be translated
into beneﬁcial effects on the vascular functions, no
improvement of the arterial stiffness or endothelial
function could be conﬁrmed after 8 weeks’ treat-
ment with azelnidipine in this study, despite the
beneﬁcial effects of the drug on the autonomic
functions. The one of possible interpretations of the
t
a
t
der; LF/HF is the ratio of low-frequency power and high-
vs. benidipine treatment.
resent results might be that the potent vasodilata-
ion effect of both CCBs overrides the inﬂuence of
ympathetic activation on vascular functions.
The present study had several limitations, as fol-
ows: (1) While the present study was conducted
o clarify whether azelnidipine might have bene-
cial effects on autonomic functions and vascular
unctions as comparing with other CCBs, all of the
tudy subjects were not denovo subjects for the
reatment with CCBs. (2) CCBs may affect the vas-
ular functions via several mechanisms other than
hrough their effects on the autonomic functions,
uch as increased NO production [33], reduction of
xidative stress [30] and differentiation of endothe-
ial progenitor cells [34]. Recent studies have
eported that benidipine increases NO production
n endothelial cells, and via this increase, the
rug may reduce the arterial stiffness and improve
ndothelial functions. Therefore, it could not be
oncluded from the results of the present study
hat the beneﬁcial effects of azelnidipine on the
utonomic functions do not affect the vascular
unctions. (3) The baseline data on the vascular
unctions, autonomic functions and oxidative stress
ere not available in this study. (4) While the equiv-
lent dosage of the two drugs is difﬁcult to deﬁne,
he ﬁnding in the present study that azelnidipine
t 16mg/day and benidipine at 4mg/day lowered
he blood pressure to a similar degree supports the
osage equivalency.
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In conclusion, azelnidpine has greater beneﬁcial
ffects on the autonomic functions than benidipine,
espite the similar degree of reduction of the blood
ressure by the two drugs. However, this beneﬁcial
ffect of the drug did not produce any distinguish-
ble differences in the effects of azelnidipine and
enidipine on the arterial stiffness and endothelial
unctions.
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